3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Ovarian Neoplasms
13
Prostatic Neoplasms
7
Fallopian Tube Neoplasms
5
Neoplasms
3
Neoplasm Metastasis
3
Breast Neoplasms
3
Prostatic Neoplasms, Castration-Resistant
2
Glioblastoma
2
Endometrial Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
SCLC,Extensive Stage
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Carcinosarcoma
1
Oropharyngeal Neoplasms
1
Mouth Neoplasms
1
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
1
Metastatic Castration-sensitive Prostate Cancer
1
Lung Neoplasms
1
Laryngeal Diseases
1
Hereditary Sensory and Autonomic Neuropathies
1
Hemangiosarcoma
1
Head and Neck Neoplasms
1
Glioma
1
Disease Progression
1
Central Nervous System Neoplasms
1
Carcinoma, Squamous Cell
1
Interventions
olaparib
1
gallium 68 PSMA-11
1
Pluvicto
1
Gemcitabine
1
Cisplatin
1
Androgen Antagonists
1
Adrenal Cortex Hormones
1
Abiraterone Acetate
1
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
1
(225)Ac-PSMA-617
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Genital Neoplasms, Male
×
niraparib
×
90 days
×
Clear all
No trials found.